SavedAdd your journal

Journals / Balkan Medical Journal / 2020 / Cilt: 37 - Sayı: 2

Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial

Sadettin KILIÇKAP
İsmail BEYPINAR
Hacer DEMİR
Özkan ALAN
Atakan DEMİR
Nuri KARADURMUŞ
Kadri ALTUNDAĞ
Gökhan DEMİR
Nil Molinas MANDEL
Yeşim ERALP
Sevil BAVBEK
Adnan AYDINER
Gül BAŞARAN
Necdet ÜSKENT
Meral GÜNALDI
Şeyda GÜNDÜZ
Murat SARI
Özlem ER
Özlem Sönmez UYSAL
Mustafa Teoman YA
Pages
104–107
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In spite of this, the activity of CDK4/6 inhibitors in patients with metastatic breast cancer who have progressed despite receiving multiple lines of treatment is not well understood.Aims: To report the activity and safety of a CDK4/6 inhibitor (palbociclib) in patients in whom at least three lines of treatment for ER+ metastatic breast cancer had failed.Study Design: Multicenter retrospective observational cohort study.Methods:Inthisretrospectiveobservationalcohortstudy,weincluded 43 patients who received palbociclib after at least three lines of systemic treatment for ER+/HER2− metastatic breast cancer.Results: The median progression-free survival in our population was 7 months (25th-75th percentile, 4-10), and the median overall survival was 11 months (25th-75th percentile, 6-19).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: The synthesis of CDK4/6 inhibitors with endocrine treatment in two series of treatment has been widely accepted as the standard for patients with estrogen receptor-positive metastatic breast cancer.
📊
Key Findings & Data:In spite of this, the activity of CDK4/6 inhibitors in patients with metastatic breast cancer who have progressed despite receiving multiple lines of treatment is not well understood.Aims: To report the activity and safety of a CDK4/6 inhibitor (palbociclib) in patients in whom at least three lines of treatment for ER+ metastatic breast cancer had failed.Study Design: Multicenter retrospective observational cohort study.Methods:Inthisretrospectiveobservationalcohortstudy,weincluded 43 patients who received palbociclib after at least three lines of systemic treatment for ER+/HER2− metastatic breast cancer.Results: The median progression-free survival in our population was 7 months (25th-75th percentile, 4-10), and the median overall survival was 11 months (25th-75th percentile, 6-19).
💡
Conclusion & Impact:Although there were some adverse events, palbociclib was generally well tolerated, so dose reduction was needed for only six patients (14%).Conclusion: The efficacy of palbociclib among heavily treated hormonereceptor-positive/HER2−patientswithadvancedbreastcancer was acceptable in terms of clinical benefit, and it was generally well tolerated among this population.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: The synthesis of CDK4/6 inhibitors with endocrine treatment in two series of treatment has been widely accepted as the standard for patients with estrogen receptor-positive metastatic breast cancer. In spite of this, the activity of CDK4/6 inhibitors in patients with metastatic breast cancer who have progressed despite receiving multiple lines of treatment is not well understood.Aims: To report the activity and safety of a CDK4/6 inhibitor (palbociclib) in patients in whom at least three lines of treatment for ER+ metastatic breast cancer had failed.Study Design: Multicenter retrospective observational cohort study.Methods:Inthisretrospectiveobservationalcohortstudy,weincluded 43 patients who received palbociclib after at least three lines of systemic treatment for ER+/HER2− metastatic breast cancer.Results: The median progression-free survival in our population was 7 months (25th-75th percentile, 4-10), and the median overall survival was 11 months (25th-75th percentile, 6-19). Although there were some adverse events, palbociclib was generally well tolerated, so dose reduction was needed for only six patients (14%).Conclusion: The efficacy of palbociclib among heavily treated hormonereceptor-positive/HER2−patientswithadvancedbreastcancer was acceptable in terms of clinical benefit, and it was generally well tolerated among this population.

🔖

Cite This Article

KILIÇKAP, S., BEYPINAR, İ., DEMİR, H., ALAN, Ö., DEMİR, A., KARADURMUŞ, N., ALTUNDAĞ, K., DEMİR, G., MANDEL, N. M., ERALP, Y., BAVBEK, S., AYDINER, A., BAŞARAN, G., ÜSKENT, N., GÜNALDI, M., GÜNDÜZ, Ş., SARI, M., ER, Ö., UYSAL, Ö. S., YA, M. T. (2022). Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial. Balkan Medical Journal, Cilt: 37 - Sayı: 2, 104–107. https://ajindex.com/articles/460912

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-403
  2. Boér K. Impact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer. Onco Targets Ther 2016;9:6119-25
  3. Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Ann Oncol 2018;29:1634-57
  4. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, et al. Breast Cancer, Version 4.2017, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw 2018;16:310-20
  5. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011;62:233-47
  6. Maurer C, Martel S, Zardavas D, Ignatiadis M. New agents for endocrine resistance in breast cancer. Breast 2017;34:1-11
  7. Augereau P, Patsouris A, Bourbouloux E, Gourmelon C, Abadie Lacourtoisie S, Berton Rigaud D, et al. Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy. Ther Adv Med Oncol 2017;9:335-46
  8. Vidula N, Rugo HS. Cyclin-dependent kinase 4/6 inhibitors for the treatment of breast cancer: a review of preclinical and clinical data. Clin Breast Cancer 2016;16:8-17
  9. Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone- receptor-positive advanced breast cancer. N Engl J Med 2015;373:209-19
  10. Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2019;17:425-39
  11. Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2-advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 2017;35:2875-84
  12. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 2016;375:1738-48
  13. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/